Astera Labs, Inc. $ALAB Position Decreased by Peregrine Investment Management Inc.

Peregrine Investment Management Inc. decreased its position in Astera Labs, Inc. (NASDAQ:ALAB) by 33.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,070 shares of the company’s stock after selling 48,970 shares during the period. Astera Labs makes up about 9.3% of Peregrine Investment Management Inc.’s portfolio, making the stock its biggest holding. Peregrine Investment Management Inc. owned about 0.06% of Astera Labs worth $19,006,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ALAB. Assetmark Inc. increased its holdings in shares of Astera Labs by 374.1% in the third quarter. Assetmark Inc. now owns 128 shares of the company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Clearstead Trust LLC increased its holdings in Astera Labs by 46,100.0% in the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after buying an additional 461 shares during the period. Advisors Asset Management Inc. raised its position in Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after buying an additional 194 shares during the last quarter. Manchester Capital Management LLC lifted its stake in Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after acquiring an additional 283 shares during the period. Finally, Whittier Trust Co. purchased a new stake in shares of Astera Labs in the 3rd quarter valued at $55,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ALAB. JPMorgan Chase & Co. boosted their target price on shares of Astera Labs from $180.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Needham & Company LLC upped their price target on Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Jefferies Financial Group reissued a “buy” rating on shares of Astera Labs in a report on Wednesday, December 3rd. Citigroup cut their price objective on Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, BNP Paribas Exane initiated coverage on Astera Labs in a research report on Thursday, November 20th. They set an “outperform” rating on the stock. Fourteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $192.89.

Astera Labs News Roundup

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q4 beat on revenue and EPS with strong growth and margins — the company reported $270.6M revenue, 75.7% gross margin and an EPS beat, and management issued solid Q1 guidance that underscores hyperscaler demand. ALAB Q4 Earnings Beat (Zacks)
• Positive Sentiment: Wall‑street analysts still see upside tied to large AI infrastructure customers (NVIDIA, AMD, Amazon, Google) and JPMorgan highlighted Astera as a beneficiary of AI buildout. That underpins medium‑term demand expectations. JPMorgan Upside Note (Benzinga)
• Neutral Sentiment: Analysts/transcripts available — full earnings call transcript and Seeking Alpha pieces provide granular color on product ramps (Scorpio X) and margin trajectory; read if you need detail on guidance cadence into H2/2027. Earnings Analysis & Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short‑interest entries appear to be data anomalies (values show 0 and NaN); no actionable evidence of a meaningful short squeeze or buildup from the published figures. Earnings Call Transcript (MSN)
• Negative Sentiment: Investors are booking profits after a massive run-up; several outlets flagged profit‑taking and a “rich” valuation as reasons for the selloff despite the beat. Profit‑Taking After Earnings (Seeking Alpha)
• Negative Sentiment: Concerns about concentration and deal terms: coverage highlighted Amazon’s reported $6.5B engagement as a “double‑edged sword” (big revenue opportunity but customer concentration/contract risk), which weighed on sentiment. Amazon Deal Concerns (MarketWatch)
• Negative Sentiment: CFO change and other corporate developments introduced near‑term uncertainty; several writeups linked management changes to the intra‑day weakness as investors reassessed execution risk. Slide After Earnings, CFO Change (Benzinga)

Insider Activity at Astera Labs

In other news, COO Sanjay Gajendra sold 90,459 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $13,088,512.71. Following the completion of the sale, the chief operating officer owned 1,599,750 shares in the company, valued at approximately $231,467,827.50. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Manuel Alba sold 150,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the transaction, the director owned 1,574,498 shares in the company, valued at approximately $261,650,077.64. This trade represents a 8.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 576,936 shares of company stock worth $87,409,540 in the last ninety days. Company insiders own 12.50% of the company’s stock.

Astera Labs Trading Down 11.9%

Shares of NASDAQ ALAB opened at $126.58 on Friday. Astera Labs, Inc. has a twelve month low of $47.13 and a twelve month high of $262.90. The stock has a fifty day simple moving average of $164.73 and a 200-day simple moving average of $174.08. The stock has a market capitalization of $21.38 billion, a PE ratio of 103.75, a PEG ratio of 1.96 and a beta of 1.50.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.87%. The firm had revenue of $270.58 million for the quarter, compared to analyst estimates of $249.46 million. During the same period last year, the business earned $0.37 EPS. Astera Labs’s revenue for the quarter was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, equities analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.